
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15â¯months: A phase III, randomized, non-inferiority trial
Keywords: MMR vaccine; Measles; Mumps; Rubella; Immunogenicity; Safety; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; HAV; hepatitis A